Cystic Fibrosis-Related Diabetes
DOI:
https://doi.org/10.69734/zz6nxh21Keywords:
Cystic Fibrosis, Cystic Fibrosis-related diabetes, diabetes mellitus, atypical diabetes, chronic pancreatitis, Metformin, GLP-1RA, GLP1 receptor agonists, DPP4 inhibitors , pancreatic cancer, insulinAbstract
Cystic fibrosis-related diabetes (CFRD) is an increasingly prevalent complication of cystic fibrosis (CF), as people with CF live longer particularly in the era of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies. Though our understanding of the underlying pathophysiology of CFRD continues to evolve, the primary defect is relative insulin deficiency resulting from reduced pancreatic beta-cell mass and impaired beta-cell function, and insulin therapy is the standard of care.
Management includes individualized insulin regimens and use of diabetes technology (e.g. insulin pumps and continuous glucose monitoring). Increasingly, dietary management, and, in select cases, non-insulin therapies can be beneficial, although long-term studies of non-insulin therapies in CFRD are few and monitoring for side effects are needed. Individuals with CFRD should be monitored for traditional microvascular and macrovascular complications of diabetes mellitus and a multidisciplinary team approach is essential. Additional long-term studies are needed to understand how CFTR modulator therapies may influence the natural history of CFRD.
References
Potter KJ, Racine F, Bonhoure A, Boudreau V, Bélanger N, Coriati A, et al. A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis. Diabetes Metab. 2023;49(4):101455.
Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. Bmj. 1995;311(7006):655-9.
Lewis C, Blackman SM, Nelson A, Oberdorfer E, Wells D, Dunitz J, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191(2):194-200.
Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-31.
Chin M, Brennan AL, Bell SC. Emerging nonpulmonary complications for adults with cystic fibrosis: adult cystic fibrosis series. Chest. 2022;161(5):1211-24.
Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992;151(9):684-7.
Hardin DS, LeBlanc A, Lukenbough S, Seilheimer DK. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr. 1997;130(6):948-56.
Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2001;32(5):343-50.
Moheet A, Moran A. New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes. J Clin Endocrinol Metab. 2022;107(6):1503-9.
Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12(4):318-31.
Kilberg MJ, Harris C, Sheikh S, Stefanovski D, Cuchel M, Kubrak C, et al. Hypoglycemia and islet dysfunction following oral glucose tolerance testing in pancreatic-insufficient cystic fibrosis. J Clin Endocrinol Metab. 2020;105(10):3179-89.
Mohan K, Miller H, Dyce P, Grainger R, Hughes R, Vora J, et al. Mechanisms of glucose intolerance in cystic fibrosis. Diabet Med. 2009;26(6):582-8.
Hardin DS, Leblanc A, Marshall G, Seilheimer DK. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab. 2001;281(5):E1022-8.
Malik SS, Padmanabhan D, Hull-Meichle RL. Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes. Front Endocrinol (Lausanne). 2023;14:1269139.
Norris AW, Ode KL, Merjaneh L, Sanda S, Yi Y, Sun X, et al. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol. 2019.
Aksit MA, Pace RG, Vecchio-Pagan B, Ling H, Rommens JM, Boelle PY, et al. Genetic modifiers of cystic fibrosis-related diabetes have extensive overlap with type 2 diabetes and related traits. J Clin Endocrinol Metab. 2020;105(5):1401-15.
Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018;19 Suppl 27:64-74.
Blackman SM, Commander CW, Watson C, Arcara KM, Strug LJ, Stonebraker JR, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes. 2013;62(10):3627-35.
Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708.
Hicks R, Marks BE, Oxman R, Moheet A. Spontaneous and iatrogenic hypoglycemia in cystic fibrosis. J Clin Transl Endocrinol. 2021;26:100267.
Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011;34(2):292-5.
Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3 Pt 1):891-5.
Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, et al. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros. 2007;6(6):376-83.
Kasim N, Khare S, Sandouk Z, Chan C. Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis. J Clin Transl Endocrinol. 2021;26:100275.
Coriati A, Potter K, Gilmour J, Lam G, Nichols C, Lands L, et al. Cystic Fibrosis Related Diabetes: a first Canadian Clinical Practice guideline. Can J Diabetes. 2024.
Sandouk Z, Khan F, Khare S, Moran A. Cystic fibrosis related diabetes (CFRD) prognosis. J Clin Transl Endocrinol. 2021;26:100278.
Gill SK, Hui K, Farne H, Garnett JP, Baines DL, Moore LS, et al. Increased airway glucose increases airway bacterial load in hyperglycaemia. Sci Rep. 2016;6:27636.
Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. Jama. 2010;303(23):2386-92.
Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146(5):681-7.
Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30(5):1056-61.
Fraser KL, Tullis DE, Sasson Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest. 1999;115(5):1321-8.
Blankenship S, Landis AR, Harrison Williams E, Peabody Lever JE, Garcia B, Solomon G, et al. What the future holds: cystic fibrosis and aging. Front Med (Lausanne). 2023;10:1340388.
Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021;78(5):1197-205.
Ahmed A, Ankireddypalli A, Harindhanavudhi T, Moran A, Moheet A. Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review. J Clin Transl Endocrinol. 2024;38:100375.
Park S, Jain R, Mirfakhraee S. Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis. J Cyst Fibros. 2025;24(1):40-6.
Patel T, McBennett K, Sankararaman S, Schindler T, Sundaram K, Minich NM, et al. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index. Pediatr Pulmonol. 2024;59(3):734-42.
Kutney KA, Sandouk Z, Desimone M, Moheet A. Obesity in cystic fibrosis. J Clin Transl Endocrinol. 2021;26:100276.
Kaminski BA, Goldsweig BK, Sidhaye A, Blackman SM, Schindler T, Moran A. Cystic fibrosis related diabetes: Nutrition and growth considerations. J Cyst Fibros. 2019;18 Suppl 2:S32-s7.
Mozzillo E, Franzese A, Valerio G, Sepe A, De Simone I, Mazzarella G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009;10(3):162-7.
Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 2009;32(10):1783-8.
Schiavon M, Cobelli C, Nair KS, Klaus K, Toffolo G, Zhang L, et al. Exogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: A randomized clinical trial. J Cyst Fibros. 2025;24(1):57-65.
Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmia E, et al. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol. 2012;6(5):1038-44.
Marks BE, Williams KM, Sherwood JS, Putman MS. Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems. J Clin Transl Endocrinol. 2022;27:100282.
Scully KJ, Marks BE, Putman MS. Advances in diabetes technology to improve the lives of people with cystic fibrosis. Diabetologia. 2024;67(10):2143-53.
Sherwood JS, Castellanos LE, O'Connor MY, Balliro CA, Hillard MA, Gaston SG, et al. Randomized trial of the insulin-only iLet Bionic Pancreas for the treatment of cystic fibrosis- related diabetes. Diabetes Care. 2024;47(1):101-8.
Onady GM, Stolfi A. Drug treatments for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2020;10(10):CD004730.
Moheet A, Moran A. Pharmacological management of cystic fibrosis related diabetes. Expert Rev Clin Pharmacol. 2018;11(2):185-91.
Sebastian-Valles F, Arranz Martín JA, Girón RM, Knott-Torcal C, Sampedro-Nuñez MA, Martin-Adan JC, et al. Continuous glucose monitoring as an additional tool in early cystic fibrosis-related diabetes monitoring and in evaluation of short-term sitagliptin response. Biomedicines. 2023;11(6).
Kelly A, Sheikh S, Stefanovski D, Peleckis AJ, Nyirjesy SC, Eiel JN, et al. Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance. J Clin Endocrinol Metab. 2021;106(9):2617-34.
Santhakumar A, Lewis F, Pickles J, Winterbottom H, Punt S, Beynon J, et al. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience. J Cyst Fibros. 2024;23(5):853-6.
Salih A II, Wills H, et al. P110 Metformin in CFRD: Outcomes from a UK Centre. Thorax. 2023;78(A17).
Brennan A EP, Bianco B, et al. P301 Metformin tolerability in patients with cystic fibrosis. J Cyst Fibrosis. 2019;18(S142).
Wynne K, Devereaux B, Dornhorst A. Diabetes of the exocrine pancreas. J Gastroenterol Hepatol. 2019;34(2):346-54.
Sapoor S, Nageh M, Shalma NM, Sharaf R, Haroun N, Salama E, et al. Bidirectional relationship between pancreatic cancer and diabetes mellitus: a comprehensive literature review. Ann Med Surg (Lond). 2024;86(6):3522-9.
Maisonneuve P, Marshall BC, Lowenfels AB. Risk of pancreatic cancer in patients with cystic fibrosis. Gut. 2007;56(9):1327-8.
Geyer MC, Sullivan T, Tai A, Morton JM, Edwards S, Martin AJ, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial. Diabetes Obes Metab. 2019;21(3):700-4.
Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-708.
Ode KL, Chan CL, Granados A, Moheet A, Moran A, Brennan AL. Cystic fibrosis related diabetes: Medical management. J Cyst Fibros. 2019;18 Suppl 2:S10-s8.
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, et al. Glycemia and insulin secretion in cystic fibrosis two years after elexacaftor/tezacaftor/ivacaftor: PROMISE-ENDO. J Clin Endocrinol Metab. 2024.
Ling H, Raraigh KS, Pugh EW, Aksit MA, Zhang P, Pace RG, et al. Genetic modifiers of body mass index in individuals with cystic fibrosis. Am J Hum Genet. 2024;111(10):2203-18.
Grancini V, Gramegna A, Zazzeron L, Alicandro G, Porcaro LL, Piedepalumbo F, et al. Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes. Diabetes Metab. 2023;49(5):101466.
Boat T, Hossain MM, Nakamura A, Hjelm M, Hardie W, Wackler M, et al. Growth, body composition, and strength of children with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor (ETI). Pediatr Pulmonol. 2025;60(1):e27463.
Putman MS, Norris AW, Hull RL, Rickels MR, Sussel L, Blackman SM, et al. Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes. 2023;72(6):677-89.
Downloads
Published
Versions
- 2025-09-20 (5)
- 2025-09-20 (4)
- 2025-06-03 (3)
- 2025-06-03 (2)
- 2025-06-03 (1)
Issue
Section
License
Copyright (c) 2025 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information